Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
A Study Evaluating Biomarkers in Participants With Heart Failure (MK-0000-344)
- Status
- WITHDRAWN
- Phase
- PHASE1
Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
- Status
- COMPLETED
- Phase
- PHASE3
Renal Integrase Study
- Status
- COMPLETED
- Phase
- PHASE4
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Outpatient Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus
- Status
- COMPLETED
- Phase
- N/A
Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
- Status
- COMPLETED
- Phase
- PHASE2
Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults
- Status
- COMPLETED
- Phase
- PHASE4
Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
- Status
- COMPLETED
- Phase
- PHASE1
The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)
- Status
- COMPLETED
- Phase
- PHASE1
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
- Status
- COMPLETED
- Phase
- PHASE2